Asset
Lonimecgene Renparvovec
Taysha Gene Therapies Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05606614 | phase3 | active_not_recruiting | 2023-03-06 | 2031-06-01 | Taysha Gene Therapies, Inc. | A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) |
| NCT06152237 | phase1_2 | active_not_recruiting | 2023-12-12 | 2028-11-02 | Taysha Gene Therapies, Inc. | Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) |
| NCT07480564 | phase3 | active_not_recruiting | 2026-05-08 | 2031-06-01 | Taysha Gene Therapies, Inc. | Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome |
FDA applications (0)
This company has no applications containing this asset.